DPLO on NYSE

Diplomat Pharmacy

Provider of specialty pharmacy services in the United States

Diplomat Pharmacy, Inc. was the largest independent provider of specialty pharmacy services in the United States. The company partners with manufacturers, payers, providers, hospitals, and more. Headquartered in Flint, Michigan, Diplomat has facilities across the United States and dispenses drugs in all 50 states.3 Its shares trade on NYSE under the symbol DPLO.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1975Founded1

Compare with another stock.

  • TickerDPLO on NYSE1
  • Industrypharmaceutical industry1
  • HeadquartersFlint1
  • Incorporated inMI5
  • Business address4100 S. Saginaw St., Flint, Mi 485075
  • Filer categoryLarge accelerated filer5
  • Legal formCorporation (For-Profit)4
  • LEI549300JMF6BE0NGN4Q454
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O UNITED AGENT GROUP INC., 48377 Novi, United States4
  • Registered withCorporations Division (Department of Licensing and Regulatory Affairs), 8001020214

Diplomat Pharmacy, Inc. was the largest independent provider of specialty pharmacy services in the United States. The company partners with manufacturers, payers, providers, hospitals, and more. Headquartered in Flint, Michigan, Diplomat has facilities across the United States and dispenses drugs in all 50 states. Diplomat offers specialized medication and medication management programs for patients with complex and chronic conditions such as cancer, hepatitis, multiple sclerosis, HIV and others.3

What it owns

What Diplomat Pharmacy reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$98.9M7 Dec 31, 2018$82.5M7 Dec 31, 2017+19.8%
Property and equipment, before depreciation$55.9M7 Dec 31, 2018$54.4M7 Dec 31, 2017+2.9%
Accumulated depreciation$21.4M7 Dec 31, 2018$15.4M7 Dec 31, 2017+39.2%
Property and equipment, net$34.5M7 Dec 31, 2018$39.0M7 Dec 31, 2017−11.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.5M7 Dec 31, 2018$84.3M7 Dec 31, 2017−88.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$609.6M7 Dec 31, 2018$832.6M7 Dec 31, 2017−26.8%
Finite-lived intangibles, gross$384.0M7 Dec 31, 2018$493.3M7 Dec 31, 2017−22.1%
Accumulated amortization$143.2M7 Dec 31, 2018$101.3M7 Dec 31, 2017+41.4%
Finite-lived intangibles, net$240.8M7 Dec 31, 2018$392.0M7 Dec 31, 2017−38.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$210.6M7 Dec 31, 2018$212.9M7 Jan 2, 2018−1.1%

The story

Dale Hagerman and his son Philip Hagerman cofounded Diplomat Pharmacy in 1975 in Flint, Michigan. In 1991, Philip Hagerman became chairman and CEO. In December 2010, Diplomat moved its headquarters back to a distribution facility in Flint from Swartz Creek, Michigan.

In 2014, Diplomat ranked 69th on the Inner City 100 list of the fastest growing companies based in inner cities. In July 2014, Diplomat acquired MedPro Rx, a specialty pharmacy based in North Carolina. In October 2014, Diplomat went public, after raising $173 million for its IPO.

In February 2015, Diplomat acquired BioRx, a specialty pharmacy in Cincinnati, Ohio for $315 million. In June 2015, Diplomat acquired Philadelphia-based Burman’s Specialty Pharmacy for $73 million.

In June 2016, Diplomat acquired Valley Campus Pharmacy Inc., doing business as TNH Advanced Specialty Pharmacy, a specialty pharmacy focusing on oncology, hepatitis, and immunology. In December 2016, Diplomat combined several subsidiary companies under one name—Diplomat Specialty Infusion Group.

In February 2017, Diplomat acquired Affinity Biotech Inc., a specialty pharmacy and infusion services company in Houston, Texas. In March 2017, Diplomat acquired Comfort Infusion, a company specializing in globulin therapy, based in Birmingham, Alabama. Comfort Infusion became part of the Diplomat Specialty Infusion Group. In May 2017, Diplomat acquired WRB Communications Inc., a provider of relationship management programs for pharmaceutical manufacturers and healthcare service organizations. In September 2017, Diplomat acquired Focus Rx Pharmacy Services Inc., a provider of home infusion and specialty prescription management services. In October 2017, Diplomat acquired 8th Day Software and Consulting LLC, based in Tennessee.

On October 9, 2017, co-founder Dale Hagerman died at the age of 90. In November 2017, Diplomat acquired Pharmaceutical Technologies Inc., doing business as National Pharmaceutical Services (NPS). NPS is a pharmacy benefit manager based in Omaha, Nebraska. In December 2017, Diplomat acquired Leehar Distributors LLC, doing business as LDI Integrated Pharmacy Services, from Nautic Partners LLC, Oak HC/FT Partners LLC, and management. LDI is a full-service pharmacy benefit manager based in St. Louis, Missouri.

On January 5, 2018, Phil Hagerman announced his retirement and Jeff Park was appointed interim CEO. In April 2018, Diplomat introduced CastiaRx, a combination of acquired pharmacy benefit managers LDI and NPS. In May 2018, Diplomat announced Brian Griffin as its new CEO and chairman of the board of directors, effective June 4, 2018. Griffin was hired from Anthem, Inc., where he served as CEO of in-house pharmacy benefit manager IngenioRx.

In December 2019, it was announced that Diplomat was being acquired by OptumRX, a subsidiary of UnitedHealth Group, for $300 million.

From Wikipedia’s article on Diplomat Pharmacy, shared under CC BY-SA 4.0.6

Leadership

Who has led Diplomat Pharmacy, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (15)

Products and brands

Diplomat distributes many medications in CarePak adherence packaging, specially designed to improve patient adherence. Diplomat also serves as the specialty pharmacy for many retail pharmacies, hospitals and health systems throughout the United States.

For hemophilia and other blood disorder patients, they offer in-home and outpatient specialty infusion services.

Accreditations

Diplomat is accredited by third-party agencies including URAC, the American Society of Health-System Pharmacists, Accreditation Commission for Health Care, Health Information Trust Alliance, and the Center for Pharmacy Practice Accreditation. The company also holds Verified-Accredited Wholesale Distributors and Verified Internet Pharmacy Practice Sites accreditations from the National Association of Boards of Pharmacy.

From Wikipedia’s article on Diplomat Pharmacy, shared under CC BY-SA 4.0.6

Timeline

  1. Jun 6, 2018New chief executive Brian T. Griffin becomes CEO9
  2. Jan 8, 2018New chief executive Jeffrey G. Park becomes CEO8
  3. Oct 9, 2014New chief executive Philip R. Hagerman becomes CEO10
  4. 1975Founded Founded1

SEC filer profile

How Diplomat Pharmacy is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDiplomat Pharmacy, Inc.2
  • CIK0001610092
  • Employer ID (EIN)38-20631002
  • Filer statusLarge accelerated filer2
  • Incorporated inMichigan2
  • Fiscal year endsDecember 312
  • Industry code (SIC)5912 Retail-Drug Stores and Proprietary Stores2
  • Business address4100 S. Saginaw St., Flint, MI 485072
  • Phone888-720-44502
  • Shares outstanding75,973,963 as of Nov 8, 201929
  • Public float$1.4B as of Jun 30, 20187
  • On EDGAR sinceJul 3, 20142
  • Filings342 in all: 4 (115), 8-K (62), SC 13G/A (26), 3 (19), 10-Q (16), SC 13G (13), UPLOAD (10), CORRESP (9)2
    All 40 form types

    CT ORDER (9), S-1/A (6), 10-K (5), DEF 14A (5), 8-K/A (4), DEFA14A (4), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), 4/A (2), 424B4 (2), 5 (2), EFFECT (2), NT 10-K (2), S-1 (2), SC TO-C (2), 10-Q/A (1), 15-12B (1), 25-NSE (1), 424B3 (1), 8-A12B (1), ARS (1), CERTNYS (1), D (1), POSASR (1), S-1MEF (1), S-3ASR (1), S-8 (1), S-8 POS (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2019
    Quarterly report (10-Q) Nov 12, 2019
    Proxy statement (DEF 14A) Apr 24, 2019
    Latest 8-K (8-K) Feb 10, 2020